Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research article
  • Open Access
  • Open Peer Review

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

  • 1,
  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 5,
  • 6,
  • 7,
  • 6,
  • 1 and
  • 1Email author
BMC Medicine201210:135

https://doi.org/10.1186/1741-7015-10-135

©  Bruera et al; licensee BioMed Central Ltd. 2012

  • Received: 21 April 2012
  • Accepted: 8 November 2012
  • Published:
Open Peer Review reports

Abstract

Background

Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated.

Methods

Tumoral and metastatic samples were screened for KRAS codon 12 and 13 and BRAF mutations by SNaPshot and/or direct sequencing. Fit MCRC patients <75 years were consecutively treated with FIr-B/FOx regimen: weekly 12-h timed flat-infusion/5-fluorouracil (TFI 5-FU) 900 mg/m2, days 1, 2, 8, 9, 15, 16, 22 and 23; irinotecan (CPT-11) 160 mg/m2 plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m2, days 8, 22; every 4 weeks. MCRC patients were classified as L-L and O/MM. Activity and efficacy were evaluated and compared using log-rank test.

Results

In all, 59 patients were evaluated: 31 KRAS wild-type (53%), 28 KRAS mutant (47%). At 21.5 months median follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively: KRAS wild-type 90%, 14 months, 38 months; KRAS mutant 67%, 11 months, 20 months. PFS and OS were not significantly different. PFS and OS were significantly different in L-L compared to O/MM evaluable patients. In KRAS wild-type patients, clinical outcome of 12 L-L compared to 18 O/MM was significantly different: PFS 21 versus 12 months and OS 47 versus 28 months, respectively. In KRAS mutant patients, the clinical outcome of 13 L-L compared to 14 O/MM was not significantly different: PFS 11 months equivalently and OS 39 versus 19 months, respectively.

Conclusions

The KRAS genotype wild-type and mutant does not significantly affect different clinical outcomes for MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may achieve a significantly prolonged clinical outcome due to integration with secondary liver surgery, with respect to KRAS mutant patients.

Keywords

  • disease extension
  • intensive regimen
  • KRAS mutations
  • metastatic colorectal cancer
  • triplet chemotherapy plus bevacizumab

Background

Triplet regimens consisting of chemotherapeutic drugs, or doublets plus bevacizumab (BEV) (anti-vascular endothelial growth factor monoclonal antibody) or cetuximab (anti-epithelial growth factor receptor (EGFR) monoclonal antibody) in EGFR-overexpressing and KRAS wild-type metastatic colorectal cancer (MCRC), reported overlapping activity and efficacy in phase III trials, ranging between objective response rate (ORR) 39% to 68%, progression-free survival (PFS) 7.2 to 10.6 months, overall survival (OS) 19.9 to 26.1 months [1]. In 'fit' MCRC patients, these first-line options, integrated with secondary resection of liver metastases, significantly increased survival over doublet regimens [1, 2]. More intensive medical treatment consisting of triplet chemotherapy plus targeted agents can further increase activity, thus raising resection rate of liver metastases and clinical outcome [1–5]. Phase II studies, by Masi et al. [3], and by our group [4], proposed BEV addition to triplet chemotherapy, according to FOLFOXIRI/BEV or FIr-B/FOx schedules, reaching ORR 77% and 82%, median PFS 13.1 and 12 months, median OS 30.9 and 28 months, as first-line treatment of MCRC patients. Liver metastasectomies were performed in 32% and 26% overall and 40% and 54% liver-only patients, respectively. Thus, MCRC patients with liver-limited (L-L) disease, integrating FIr-B/FOx intensive regimen and secondary liver surgery significantly improved clinical outcome compared to MCRC patients with multiple metastatic disease, up to median PFS 17 months and median OS 44 months [6].

Gain-of-function mutations of RAS, BRAF, PIK3CA genes, or loss of tumor suppressor function of PTEN, resulting in continuous activation of the RAS-mitogen-activated protein kinase (MAPK) or phosphoinositide 3-kinase (PI3K) pathways, characterize most colorectal cancers (CRC) [7–9]. KRAS mutations represent an early event in colorectal tumorigenesis [10, 11] and occur in 35% to 45% of CRC, mostly represented by codon 12 c.35 G>A (32.5%) [12, 13], c.35 G>T (22.5%) [11, 12], and codon 13, prevalently c.38 G>A, transversions [14]. They impair intrinsic GTPase activity of KRAS, and lead to constitutive, growth factor receptor-independent activation of downstream signaling [15]. BRAF mutations, prevalently c.1799 T>A (V600E) mutation, characterize 4.7% to 8.7% of CRC [16–20].

Clinical outcome (PFS, OS) according to wild-type and mutant genotype assesses the prognostic relevance of a specific biomarker, potentially including the predictive role of effectiveness of treatment strategies. In randomized studies, the predictive relevance of wild-type or mutant genotype can also be specifically assessed by comparing experimental and control arms. The reported median OS values of KRAS wild-type and mutant MCRC patients treated with irinotecan, 5-fluorouracil and leucovorin (IFL) plus BEV were 27.7 and 19.9 months, respectively [18, 21]. The prognostic relevance of KRAS or BRAF wild-type compared to KRAS or BRAF mutant genotype was not significantly different, even though the hazard ratio (HR) was 0.64 and 0.38, respectively. A significantly better prognosis was reported only when KRAS/BRAF wild-type patients were compared with patients harboring mutations in the KRAS or BRAF genes (HR 0.51) [18]. KRAS wild-type genotype significantly predicts a favorable clinical outcome of anti-EGFR or anti-vascular endothelial growth factor (VEGF) drugs added to doublet chemotherapy [18, 21–23]. In the KRAS mutant genotype, BEV addition to IFL significantly prolonged PFS up to 9.3 months, without increasing OS and activity, compared to IFL [18, 21].

Here, we report a retrospective exploratory analysis evaluating the prognostic value of the KRAS genotype in MCRC patients enrolled in a previously reported phase II study [4] and in an expanded clinical program proposing FIr-B/FOx intensive regimen as first-line treatment, also verifying recently reported significantly greater effectiveness in L-L compared to other or multiple metastatic (O/MM) patients [6].

Methods

Patient eligibility

MCRC patients were enrolled in a previously reported phase II study [4] and in the expanded clinical program proposing FIr-B/FOx association as first-line treatment. Patients were eligible if they had a histologically confirmed diagnosis of measurable MCRC; were age 18 to 75 years; had World Health Organization (WHO) performance status ≤2; had adequate hematological, renal and hepatic functions; and had a life expectancy more than 3 months. The study was approved by the Local Ethical Committee (Comitato Etico, Azienda Sanitaria Locale n.4 L'Aquila, Regione Abruzzo, Italia) and conducted in accordance with the Declaration of Helsinki. All patients provided written, informed consent.

Schedule

The FIr-B/FOx regimen was developed from previously reported doublet and triplet chemotherapy schedules [24, 25], consisting of weekly timed flat-infusion/5-fluorouracil (TFI 5-FU), without leucovorin, associated to weekly alternating irinotecan (CPT-11)/BEV or L-oxaliplatin (OXP) [4]: TFI 5-FU (Fluorouracil Teva; Teva Italia, Milan, Italy), 900 mg/m2/day, over 12 h (from 10:00 pm to 10:00 am), days 1, 2, 8, 9, 15, 16, 22 and 23; CPT-11 (Campto; Pfizer, Latina, Italy), 160 mg/m2, days 1, 15; BEV (Avastin; Roche, Welwyn Garden City, United Kingdom), 5 mg/kg, days 1, 15; l-OXP (Eloxatin; Sanofi-Aventis, Milan, Italy), 80 mg/m2, days 8, 22; cycles every 4 weeks.

Mutational analysis

KRAS and BRAF genetic analyses were performed on paraffin-embedded tissue blocks from the primary tumor and/or metastatic sites. Genotype status was assessed for KRAS codon 12 and 13 mutations and BRAF c.1799 T>A (V600E) mutation by SNaPshot® multiplex screening for KRAS mutations and KRAS/BRAF mutations in 36 and 32 samples, respectively [26, 27]; direct sequencing was performed for detection of KRAS mutations in 23 samples and to confirm detected mutations. After treatment with xylene thyocyanate and selection of tumoral cell clusters, DNA was isolated using the RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE Tissues (Applied Biosystems, Courtaboeuf, France) according to manufacturer's instructions. When considering the contamination of tumoral samples by non-malignant cells, a KRAS mutation in the tumor was defined as appearance of a mutant peak with a height of at least one-third compared to the wild-type.

SNaPshot and Direct Sequencing assays

SNaPshot multiplex assay was performed as elsewhere reported [26, 27]. Briefly, KRAS exon 2 and BRAF exon 15 were simultaneously amplified by polymerase chain reaction (PCR) using specific primers and purified using NucleoSpin® Extract II kit (Macherey-Nagel EURL, Hoerdt, France). PCR-amplified DNA was analyzed using the ABI PRISM SNaPshot Multiplex kit (Applied Biosystems, Foster City, CA, USA) and five primers including an additional tail at their 5' end allowing their simultaneous detection. Sense primers allowing the extension at nucleotides KRAS c.34G, c.35G, c.37G, c.38G and BRAF c.1799T were used and a multiplex SNaPshot reaction was performed as reported [26]. KRAS exon 2 sequencing was performed from PCR-amplified tumor DNA using the Big Dye V3.1 Terminator Kit (Applied Biosystems, Foster City, CA, USA). Labeled products were separated using an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Data were analyzed using the GeneMapper Analysis Software version 4.0 (Applied Biosystems, Foster City, CA, USA).

Study design

A retrospective analysis was planned to evaluate prognostic relevance of KRAS genotype on clinical outcome of MCRC patients treated with FIr-B/FOx as first-line treatment. Moreover, patients were classified according to involved metastatic sites, L-L and O/MM [6], to evaluate the relevance of metastatic extension in KRAS wild-type and mutant MCRC patients. Patients with L-L metastases were evaluated at baseline and every three cycles of treatment by a multidisciplinary team, consisting of a medical oncologist, liver surgeon and radiologist, to dynamically evaluate resectability defined according to resectability categories previously reported [6]. Resection rate was evaluated in the intent-to-treat population enrolled. Liver metastasectomies were defined as R0, if radical surgery, R1, if radioablation was added. Surgery was recommended >4 weeks after BEV discontinuation. Clinical evaluation of response was made by computed tomography (CT) scan; positron emission tomography (PET) was added based on investigators' assessment.

Clinical criteria of activity and efficacy were ORR, PFS and OS. ORR was evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria [28]; pathologic complete response was defined as absence of residual cancer cells in surgically resected specimens. The overall activity of integrated medical treatment and secondary liver surgery, consisting of the sum of clinical complete responses (cCR) and liver metastasectomies was also evaluated, as previously reported [6]. PFS and OS were evaluated using the Kaplan-Meier method [29]. PFS and PFS from surgery were defined, respectively, as the length of time from the beginning of treatment or the date of liver metastasectomy and disease progression or death (resulting from any cause) or to the last contact; OS as the length of time between the beginning of treatment and death or to last contact. The Log-rank test was used to compare PFS and OS in KRAS wild-type versus mutant, L-L versus O/MM, and KRAS wild-type L-L versus O/MM, and KRAS mutant L-L versus O/MM MCRC patients [30].

Results

Patient demographics

A total of 59 tumoral samples of 64 enrolled MCRC patients (92%) were available: 46 primary tumors and 13 metastases (7 liver, 4 peritoneal carcinomatosis, 1 local recurrence and 1 lung). Demographic and baseline features of patients were representative of the overall phase II study population (Table 1). The number of MCRC patients with KRAS wild-type and mutant genotypes was 31 (53%) and 28 (47%), respectively (Table 1); the male/female ratio was 21/10 and 16/12; synchronous metastatic disease, 21 (68%) and 21 (75%) patients. Patients' distribution according to extension of metastatic disease, L-L and O/MM, was, respectively: overall, 25 (42%) and 34 (58%); KRAS wild-type, 12 (39%) and 19 (61%); KRAS mutant, 13 (46%) and 15 (54%). Table 2 shows KRAS mutations detected in 28 patients: codon 12, 24 patients (85.7%), specifically c.35 G>A 15 patients (53.5%), c.35 G>T 7 patients (25%), c.34 G>A and c.35 G>C, 1 patient each; codon 13, 4 patients (14.2%), c.38 G>A 3 patients (10.7%) and c.37_39 dupl, 1 patient. A total of 32 tumoral samples (54%) were also analyzed for BRAF and no BRAF mutation was detected; 18 out of 31 KRAS wild-type MCRC patients were KRAS and BRAF wild-type; 14 out of 28 KRAS mutant MCRC patients were BRAF wild-type. EGFR protein expression was positive in 35 patients (59%) and negative in 24 patients (41%): among KRAS wild-type patients, positive in 23 patients (74%) and negative in 8 patients (26%); among KRAS mutant patients, positive in 13 patients (40%) and negative in 15 patients (60%).
Table 1

Patients' features

 

KRASwild-type, no. (%)

KRASmutant, no. (%)

Total no. (%)

No. of patients

31 (53)

28 (47)

59

Male/female

21/10

16/12

37/22

Age, years:

   

Median

64

65

63

Range

42 to 73

48 to 73

42 to 73

≥65

13 (42)

13 (46)

26 (44)

WHO performance status:

   

0

28 (90)

26 (93)

54 (92)

1 to 2

3 (10)

2 (7)

5 (8)

Metastatic disease:

   

Metachronous

10 (32)

7 (25)

17 (29)

Synchronous

21 (68)

21 (75)

42 (71)

Primary tumor:

   

Colon

14 (45)

20 (71)

34 (58)

Rectum

17 (55)

8 (29)

25 (42)

Sites of metastases:

   

Liver

19 (61)

20 (71)

39 (66)

Lung

7 (23)

5 (18)

12 (20)

Lymph nodes

10 (32)

8 (29)

18 (30)

Local

6 (19)

3 (11)

9 (15)

Other

2 (6)

6 (21)

8 (14)

No. of involved sites:

   

1

17 (55)

17 (61)

34 (58)

≥2

14 (45)

11 (39)

25 (42)

Single metastatic sites:

   

Liver limited

12 (39)

13 (46)

25 (42)

Other than liver

7 (22)

4 (15)

11 (19)

   Lung

   2 (6)

   2 (7)

   4 (7)

   Lymph nodes

   2 (6)

   1 (4)

   3 (5)

   Local

   3 (10)

   1 (4)

   4 (7)

Multiple metastatic sites

12 (39)

11 (39)

23 (39)

Liver metastases:

   

Single

8 (26)

3 (11)

11 (19)

Multiple

11 (35)

11 (39)

22 (37)

Previous adjuvant chemotherapy:

6 (19)

2 (7)

8 (14)

FA/5-FU bolus

3 (10)

-

3 (5)

Capecitabine

-

-

-

FOLFOX4

2 (6)

2 (7)

4 (7)

XelOx

1 (3)

-

1 (2)

Previous radiotherapy:

4 (13)

1 (4)

5 (8)

Radiotherapy alone

-

-

-

Radiotherapy + chemotherapy (5-FU continuous infusion)

2 (6)

-

2 (3)

Radiotherapy + chemotherapy (XELOX)

2 (6)

1 (4)

3 (5)

WHO = World Health Organization.

Table 2

KRAS mutations

Exon

Codon

Hot spot site

Amino acid

No. of patients

%

2

12

  

24

40.6

  

c.34 G>A

p.Gly12Ser

1

1.6

  

c.35 G>A

p.Gly12Asp

15

25.4

  

c.35 G>T

p.Gly12Val

7

11.8

  

c.35 G>C

p.Gly12Ala

1

1.6

 

13

  

4

6.7

  

c.37_39 dupl

p.Gly13 dupl

1

1.6

  

c.37

-

-

-

  

c.38 G>A

p.Gly13Asp

3

5

Activity and efficacy

Overall activity and efficacy data (Table 3) were similar to that reported in the phase II study: ORR was 79% (95% CI 68 to 90); liver metastasectomies were performed in 18 patients (31%), 17 out of 25 L-L patients (68%). After a median follow-up of 21.5 months, median PFS was 12 months (1+ to 69+ months), median OS was 28 months (1+ to 69+ months). Among 30 evaluable KRAS wild-type patients, ORR was 90% (95% CI 79 to 100). We observed 27 objective responses: 23 partial responses (77%) and 4 complete responses (CRs) (13%); 2 stable diseases (7%); 1 progressive disease (3%). Disease control rate was 97% (95% CI 90 to 100). Liver metastasectomies were performed in 11 patients (35%), 10 out of 12 L-L patients (83%). Median PFS was 14 months (1+ to 69+ months), 25 events occurred. Median OS was 38 months (1+ to 69+ months), 17 events occurred. Among the 18 KRAS/BRAF wild-type patients, ORR was 83% (95% CI 69 to 97), median PFS was 13 months (4 to 44 months), median OS was 31 months (8 to 66+ months). Among 27 evaluable KRAS mutant patients, ORR was 67% (95% CI 49 to 85). We observed 18 objective responses: 17 partial responses (63%) and 1 CR (4%); 4 progressive diseases (16%). Disease control rate was 85% (95% CI 71 to 99). Liver metastasectomies were performed in 7 patients (25%) out of 13 L-L patients (54%). Median PFS was 11 months (1+ to 60+ months), 20 events occurred. Median OS was 20 months (1+ to 60+ months), 17 events occurred. Overall, R0 liver resections made up 13 out of 18 liver metastasectomies (72%). Pathologic CRs were obtained in 2 patients (11%), both KRAS mutant patients, harboring codon 12 mutations, c.35 G>T and c.34 G>A, with multiple liver-only metastases. In one KRAS wild-type patient with single liver associated with lung metastases, double metastatic resections were performed. KRAS wild-type compared with mutant patients did not show significantly different PFS nor OS, even if OS seems to be favorable in KRAS wild-type patients (Figure 1).
Table 3

Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype

 

Intent to treat analysis

 

KRASwild-type

KRASmutant

All

 

No

%

No

%

No

%

Enrolled patients

31

100

28

100

59

100

Evaluable patients

30

97

27

96

57

97

Objective response

27

90 (95% CI 79 to 100)

18

67 (95% CI 49 to 85)

45

79 (95% CI 68 to 100)

Partial response

23

77

17

63

40

70

Complete response

4

13

1

4

4

7

Stable disease

2

7

5

18.5

7

12

Progressive disease

1

3

4

15

5

9

Median PFS, months

14

 

11

 

12

 

Range

1+-69+

 

1+-60+

 

1+-69+

 

Progression events

25

81

20

71

45

76

Median OS, months

38

 

20

 

28

 

Range

1+-69+

 

1+-60+

 

1+-69+

 

Deaths

17

55

17

61

34

58

Liver metastasectomies

11

 

7

 

18

 

No/overall patients

11/31

35

7/28

25

18/59

31

No/patients with liver metastases

11/19

58

7/20

35

18/39

46

No/patients with L-L metastases

10/12

83

7/13

54

17/25

68

Pathologic complete responses

-

-

2

28.5

2

11

L-L = liver limited; OS = overall survival; PFS = progression-free survival.

Figure 1
Figure 1

Kaplan-Meier survival estimate. Overall population, KRAS wild-type versus KRAS mutant. 1, Progression-free survival; 2, overall survival.

We verified previously reported findings of significantly different outcome (PFS and OS) with FIr-B/FOx according to extension of metastatic disease [6] in KRAS wild-type and mutant patients (Table 4). Among 25 evaluable L-L patients, ORR was 84% (95% CI 69 to 99); overall activity was 80% due to 17 performed liver metastasectomies (68%) and 3 cCRs (12%) in patients who did not undergo liver surgery showing PFS of 69+, 60+, and 40+ months, respectively; median PFS was 17 months (3 to 69+ months); median OS was 47 months (8 to 69+ months). Among the 17 L-L patients who underwent liver metastasectomies, the median PFS was 18 months (8 to 35+ months); median OS was 47 months (10+ to 56+ months). Among 32 evaluable O/MM patients, the ORR was 80% (95% CI 64 to 96), overall activity was 9% due to 1 performed liver plus lung metastasectomies (3%) and 2 cCRs (6%) in patients who did not undergo liver surgery and showing PFS of 22, and 4+ months, respectively; median PFS was 12 months (1+ to 44 months); median OS was 21 months (1+ to 66+ months). Clinical outcome (PFS and OS) in L-L compared to O/MM patients was significantly different (Figure 2A).
Table 4

Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype and extension of metastatic disease

 

All

KRASwild-type

KRASmutant

 

L-L

O/MM

L-L

O/MM

L-L

O/MM

Evaluable patients

25

32

12

18

13

14

Objective response (%; 95% CI)

21 (84; 69 to 99)

24 (80; 64 to 96)

12 (100)

15 (80; 59 to 100)

9 (67; 40 to 94)

9 (80; 54 to 100)

Partial response

18

22

10

13

8

9

Complete response

3 (12)

2 (6)

2 (17)

2 (11)

1 (8)

-

Stable disease

2

3

-

2

2

3

Progressive disease

2

3

-

1

2

2

Liver metastasectomies, N (%)

17 (68)

1 (3)

10 (83)

1 (6)

7 (54)

-

Pathologic complete responses

2 (12)

-

-

-

2

-

Overall activitya, N (%)

20 (80)

3 (9)

12 (100)

3 (17)

8 (62)

-

Median PFS, months

17

12

21

12

11

11

Range

3-69+

1+44

8-69+

4-44

3-60+

1+37

Progression events

20

27

10

15

10

12

P value

0.034

0.044

0.354

Median OS, months

47

21

47

28

39

19

Range

8-69+

1+66+

18+69+

1+66+

8-60+

1+59+

Deaths

12

23

4

13

8

10

P value

0.013

0.017

0.225

aClinical complete response plus metastasectomies.

L-L = liver limited; O/MM = other/multiple metastatic site; OS = overall survival; PFS = progression-free survival.

Figure 2
Figure 2

Overall survival, Kaplan-Meier survival estimate. (A) Liver only versus multiple metastatic sites; (B) liver-only versus multiple metastatic sites, KRAS wild-type; (C) liver-only versus multiple metastatic sites, KRAS mutant. 1, Progression-free survival; 2, overall survival.

Among the 30 evaluable KRAS wild-type patients, ORR in 12 L-L and 18 O/MM patients were 100% and 80%, respectively. Overall activity was 100% (ten liver metastasectomies and two cCRs) in L-L and 17% (one liver plus lung metastasectomy and two cCRs) in O/MM patients, respectively. Significantly different clinical outcome was confirmed in L-L compared to O/MM, respectively (Figure 2B): median PFS 21 months (8 to 69+ months) versus 12 months (4 to 44 months) (p 0.044); median OS 47 months (18+ to 69+ months) versus 28 months (1+ to 66+ months) (p 0.017). Among the 27 evaluable KRAS mutant patients, ORR in 13 L-L and 14 O/MM patients were 67% and 80%, respectively. Overall activity in L-L patients was 62% (seven liver metastasectomies and one cCR) while no liver metastasectomy nor cCR was obtained in O/MM patients. The comparison of PFS and OS in KRAS mutant L-L and O/MM patients was not significantly different: median PFS 11 months (3 to 60+ months) versus 11 months (1+ to 37 months), respectively; median OS 39 months (8 to 60+ months) versus 19 months (1+ to 59+ months), respectively (Figure 2C).

Discussion

In KRAS wild-type patients, BEV addition to doublet chemotherapy significantly increased ORR, PFS and OS up to 60% to 61%, 10.5 to 13.5 months and 21.8 to 27.7 months, respectively [18, 21, 31, 32]. Randomized studies of anti-EGFR added to doublets, in EGFR-overexpressing patients, reported ORR 50% to 61%, PFS 7.7 to 10.6 months, OS 22.4 to 24.9 months [22, 23, 31–33]. First-line cetuximab plus FOLFOX4, significantly improved ORR and PFS in KRAS/BRAF wild-type population, similarly to KRAS wild-type patients [34]. In KRAS mutant patients, BEV addition to doublet chemotherapy (IFL) significantly increased median PFS up to 9.3 months, while ORR was equivalent to doublet arm (43.2% and 41.2%, respectively), and median OS increased up to 19.9 months, even if not significantly [21, 35].

In KRAS wild-type and mutant MCRC patients, BEV addition to triplet chemotherapy, according to FIr-B/FOx schedule, reported high activity and efficacy: ORR 90% and 67%, median PFS 14 and 11 months, median OS 38 and 20 months, respectively. A similar clinical outcome was also obtained in KRAS/BRAF wild-type patients. Equivalent efficacy was reported with FOLFOXIRI/BEV regimen: ORR 82% and 71%, median PFS 13.6 and 12.6 months, respectively [3]. In unresectable colorectal liver metastases, ORR 79%, median PFS 14 months, median OS 37 months were reported with chrono-IFLO/cetuximab [5].

Median PFS and OS values of MCRC patients treated with FIr-B/FOx were different in KRAS wild-type and mutant patients, even if not significantly, while they were equivalent in the FOLFOXIRI plus BEV study [3]. BEV addition to doublet IFL chemotherapy gave median PFS 13.5 and 9.3 months, median OS 27.7 and 19.9 months in KRAS wild-type and mutant patients, respectively [18, 21]. Significantly better prognosis was reported in KRAS/BRAF wild-type patients compared with patients harboring mutations in the KRAS or BRAF genes (HR 0.51) [18]. Direct comparison of OS between KRAS wild-type and mutant MCRC patients treated with BEV-containing chemotherapy failed to significantly differentiate prognosis, as in the present study. Thus, intensive regimens adding BEV to triplet chemotherapy can further increase activity and efficacy in KRAS wild-type and mutant patients. Randomized studies would be able to properly evaluate this.

The high activity of triplet chemotherapy plus BEV regimens correlated with increased resection rate of liver metastases and pathologic CR, particularly in L-L MCRC patients [1, 3, 4, 6]. We recently reported that the clinical outcome of L-L compared to multiple metastatic disease was significantly improved up to median PFS 17 months and median OS 44 months [6] due to the effectiveness of integrated FIr-B/FOx intensive treatment and secondary liver surgery. The present analysis confirms the significantly favorable prognosis of L-L compared to MM patients and show that KRAS wild-type L-L patients, accounting for 20% of fit MCRC patients, could gain 100% overall activity with an integrated medical and surgical approach, due to performed liver metastasectomies and long-lasting cCRs; median PFS 21 months and OS 47 months. A significantly favorable prognosis was demonstrated in KRAS wild-type L-L compared to O/MM patients, even if this represents a retrospective, exploratory analysis in a small cohort of MCRC patients. Using neoadjuvant cetuximab with either FOLFOX6 or FOLFIRI for unresectable colorectal liver metastases, metastasectomies were performed in 38% and 30% patients, respectively [36]. Chrono-IFLO/cetuximab reported a 60% R0 resection rate in unresectable colorectal liver metastases, with ORR 79%, median PFS 14 months and median OS 37 months [5]. Further prospective studies will properly address whether intensive medical treatments, such as FIr-B/FOx, and secondary liver surgery could represent the standard multidisciplinary strategy for KRAS wild-type L-L MCRC patients. In KRAS mutant patients, prevalently harboring c.35 G>A transversion (53.5%), integrated medical and surgical treatment failed to significantly increase PFS and OS in L-L compared to O/MM patients: median PFS was equivalent (11 months), in spite of 54% performed liver metastasectomies in L-L patients; median OS was 39 and 19 months, respectively. These data should be further evaluated in a larger cohort of MCRC patients. A proper multidisciplinary treatment strategy for KRAS mutant patients, showing different aggressiveness [37], sensitivity to medical treatment, and worse clinical behavior, is an unmet need.

Conclusions

KRAS wild-type and mutant genotypes do not significantly affect the clinical outcomes of MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may achieve significantly greater benefit from integration with liver metastasectomies compared to O/MM metastatic extension, with respect to KRAS mutant patients. The present findings should be verified in prospective trials of multidisciplinary strategies comparing clinical outcome according to KRAS genotype in patients with L-L and O/MM disease.

Declarations

Authors’ Affiliations

(1)
Medical Oncology, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy
(2)
Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
(3)
Laboratory of Tumor Genetics, University Hospital, Rouen, France
(4)
Department of Biomorphologic and Functional Sciences, University Federico II, Napoli, Italy
(5)
Pathology Department, S. Salvatore Hospital, L'Aquila, Italy
(6)
INSERM U614, University of Rouen, Rouen, France
(7)
Department of Pathology, INSERM U614, Rouen University Hospital, Rouen, France

References

  1. Bruera G, Ricevuto E: Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52. Exp Opin Biol Ther. 2011, 11: 821-824. 10.1517/14712598.2011.582462.View ArticleGoogle Scholar
  2. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Pugliesi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A: Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011, 103: 21-30. 10.1093/jnci/djq456.View ArticlePubMedGoogle Scholar
  3. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010, 11: 845-852. 10.1016/S1470-2045(10)70175-3.View ArticlePubMedGoogle Scholar
  4. Bruera G, Santomaggio A, Cannita K, Lanfiuti Baldi P, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E: "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer. 2010, 10: 67-10.1186/1471-2407-10-67.View ArticleGoogle Scholar
  5. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F: Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadiuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010, 103: 1542-1547. 10.1038/sj.bjc.6605940.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E: Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2012, 11: 119-126. 10.1016/j.clcc.2011.11.002.View ArticlePubMedGoogle Scholar
  7. Yarden Y, Sliwkowsky MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.View ArticlePubMedGoogle Scholar
  8. Scaltriti M, Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006, 12: 5268-5272. 10.1158/1078-0432.CCR-05-1554.View ArticlePubMedGoogle Scholar
  9. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006, 46: 249-279. 10.1016/j.advenzreg.2006.01.004.View ArticlePubMedGoogle Scholar
  10. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR: Cosmic 2005. Br J Cancer. 2006, 94: 318-322. 10.1038/sj.bjc.6602928.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 1989, 49: 4682-4689.PubMedGoogle Scholar
  12. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young Y, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JWC, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, et al: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001, 85: 692-696. 10.1054/bjoc.2001.1964.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Normanno N, Tejpar S, Morbillo F, De Luca A, Van Cutsem E, Ciardiello F: Implication of KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Onc. 2009, 6: 519-527. 10.1038/nrclinonc.2009.111.View ArticleGoogle Scholar
  14. Schubbert S, Shannon K, Bollag G: Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer. 2007, 7: 295-308. 10.1038/nrc2109.View ArticlePubMedGoogle Scholar
  15. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11: 753-762. 10.1016/S1470-2045(10)70130-3.View ArticlePubMedGoogle Scholar
  16. Zauber P, Sabbath-Solitare M, Marotta SP, Bishop DT: Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchorous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003, 56: 137-140. 10.1136/mp.56.3.137.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Artale S, Sartore-Bianchi A, Veronese S, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008, 26: 4217-4219. 10.1200/JCO.2008.18.7286.View ArticlePubMedGoogle Scholar
  18. Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008, 14: 4830-4835. 10.1158/1078-0432.CCR-07-4906.View ArticlePubMedGoogle Scholar
  19. Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, Colomba P, Tagliavia M, La Farina M: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of K-ras and p53 mutations. Biochem Biophys Res Commun. 2004, 325: 784-791. 10.1016/j.bbrc.2004.10.111.View ArticlePubMedGoogle Scholar
  20. Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S: Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991, 49: 875-879. 10.1002/ijc.2910490613.View ArticlePubMedGoogle Scholar
  21. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009, 14: 22-28.View ArticlePubMedGoogle Scholar
  22. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009, 351: 1408-1417.View ArticleGoogle Scholar
  23. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucoverin, and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009, 27: 663-671. 10.1200/JCO.2008.20.8397.View ArticlePubMedGoogle Scholar
  24. Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P: Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: a dose-finding study. Oncol Rep. 2006, 15: 1345-1350.PubMedGoogle Scholar
  25. Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti Baldi P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C, on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia): Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep. 2010, 23: 1635-40.PubMedGoogle Scholar
  26. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboué R, Tuech JJ, Queniet AM, Paillot B, Sabouirin JC, Michot F, Michel P, Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007, 96: 1166-1169. 10.1038/sj.bjc.6603685.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Lamy A, Blanchard F, Le Pessot F, Sesboué R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol. 2011, 24: 1090-1100. 10.1038/modpathol.2011.60.View ArticlePubMedGoogle Scholar
  28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093/jnci/92.3.205.View ArticlePubMedGoogle Scholar
  29. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.View ArticleGoogle Scholar
  30. Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R Stat Soc A. 1972, 135: 185-206. 10.2307/2344317.View ArticleGoogle Scholar
  31. Hecht JR, Mitchell E, Chidiac T, scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009, 27: 672-680. 10.1200/JCO.2008.19.8135.View ArticlePubMedGoogle Scholar
  32. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JHJM, Dalesio O, Punt CJA: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009, 360: 563-572. 10.1056/NEJMoa0808268.View ArticlePubMedGoogle Scholar
  33. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocàkova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: Randomized, phase III trial of Panitumumab with infusional fluorouracil, leicovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME trial. J Clin Oncol. 2010, 28: 4697-4705. 10.1200/JCO.2009.27.4860.View ArticlePubMedGoogle Scholar
  34. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011, 22: 1535-1546. 10.1093/annonc/mdq632.View ArticlePubMedGoogle Scholar
  35. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005, 97: 981-989. 10.1093/jnci/dji174.View ArticlePubMedGoogle Scholar
  36. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with Cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol. 2010, 11: 38-47. 10.1016/S1470-2045(09)70330-4.View ArticlePubMedGoogle Scholar
  37. Guerrero S, Casanova I, Farrè L, Mazo A, Capellà G, Mangues R: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000, 60: 6750-6756.PubMedGoogle Scholar

    38. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/135/prepub

Copyright

© Bruera et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Medicine

ISSN: 1741-7015

Contact us